Dermatitis

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo nodularis in the European Union, Galderma announced in a press release.

Self-guided cognitive behavioral therapy was non-inferior in reducing atopic dermatitis symptom severity as clinician-guided cognitive behavioral therapy, according to a study.

Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of tralokinumab for the treatment of atopic dermatitis.

Nektar Therapeutics has completed target enrollment for its phase 2b study of rezpegaldesleukin for the treatment of patients with moderate to severe atopic dermatitis, the company announced in a press release.

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating the efficacy of the ointment’s 2% formulation, the company announced in a press release.

Severe disease, male sex, family history and prenatal factors were significantly associated with an increased risk for atopic march progression in infants with atopic dermatitis, according to a study.

The year 2024 was important for skin disorders with many innovations and breakthroughs.

The FDA has cleared the investigational new drug application for STAR-0310 as a potential treatment for atopic dermatitis and other diseases, Astria Therapeutics announced in a press release.

BOSTON — Daily tapinarof cream 1% improved weekly itch outcomes and sleep in patients with atopic dermatitis and pruritus, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

BOSTON — Roflumilast cream improved signs and symptoms of atopic dermatitis, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.